NEONC TECHNOLOGIES HOLDINGS, INC.
Close on Oct 19, 2026
- Market cap
- $67.09M
- P/E (TTM)
- –
- Dividend yield
- –
About Neonc Technologies
Pharmaceutical Preparations, SIC 2834
NeOnc Technologies is a clinical-stage biopharmaceutical company focused on developing therapies and novel delivery modalities for intracranial malignancies, including primary brain tumors such as glioblastoma and meningioma, as well as secondary brain metastases. The company's pipeline centers on two investigational candidates: NEO100, a purified perillyl alcohol administered intranasally to bypass the blood-brain barrier, and NEO212, an oral and intranasal conjugate of temozolomide and perillyl alcohol. NeOnc currently conducts human clinical trials across targeted patient populations lacking effective alternatives, while also exploring delivery applications for neurodegenerative conditions.
The company operates without commercial products, revenue-generating customer accounts, or internal sales infrastructure, relying on clinical trials and regulatory reviews to advance its pipeline. Corporate operations and sponsored clinical research are based out of Los Angeles, California. In addition to multi-institutional clinical trial sites across the United States, NeOnc engages in collaborative research partnerships, including initiatives extending clinical development into the Gulf Cooperation Council region.
Summary of the business section of Neonc Technologies's latest annual report, written by StockData.
Company profile
Company
- Legal name
- NEONC TECHNOLOGIES HOLDINGS, INC.
- Founded
- 2008
- Headquarters
- Calabasas, CA
- Address
- 23975 Park Sorrento, Suite 205 91302
- Phone
- (310) 663-7831
- Employees
- 5, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Marcum llp, Philadelphia, PA
Stock & identifiers
- Ticker
- NTHI
- Exchange
- Nasdaq
- IPO date
- Mar 25, 2025
- Shares outstanding
- 26M, Aug 10, 2026
- Public float
- $67.90M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1979414
- CUSIP
- 64051A101
- ISIN
- US64051A1016
- EIN
- 92-1954864
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Amir F. Heshmatpour | CEO, President, Director | 7,703,140 |
| Thomas C. Chen | CEO, Director | 4,685,586 |
| Keithly Garnett | CFO | 281,410 |
| Yousha Neman-Ebrahim | Chief Clinical Officer | 134,760 |
| Suh, David Jr. | Chief Accounting Officer | 111,866 |
| Patrick Walters | COO | 876,373 |
| Nasim Shomali | Director | 50,160 |
| Ming-Fu (Alan) Chiang | Director | 2,190,049 |
| Ishwar Kanwar Puri | Director | – |
| Jim Delshad | Director | 55,310 |
| Steven L. Giannotta | Director | 50,160 |
| Bader Almonawer | Director | 50,160 |
| Victoria Medvec | Director | 50,160 |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 22, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Aug 14, 2025 | Late filing | Notification of late filing |
| Apr 1, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Mar 25, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 24, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |